Please login to the form below

Not currently logged in
Email:
Password:

Sanofi appoints NIH’s Gary Nabel as chief scientific officer

He previously headed vaccine research centre of the US National Institute of Allergy and Infectious Diseases

Gary Nabel, SanofiDr Gary Nabel has left US medical research centre the National Institutes of Health (NIH) to join Sanofi as senior VP, chief scientific officer and deputy to the president for global R&D.

In his new role, he will hold responsibility for Sanofi's scientific strategy for all of its units, including pharmaceuticals, animal health and vaccines, and will focus on improving translational approaches in research.

Dr Nabel will be based at Sanofi's offices in Cambridge, Massachusetts – the city he studied in during his time as Harvard University.

“I am very excited that Dr Nabel will join Sanofi's R&D organisation,” said Dr Elias Zerhouni, president, global R&D, Sanofi. “Our challenges today require that we re-invent our R&D model. Gary's experience will be invaluable to help us achieve this goal.”

Dr Nabel leaves the NIH, which is part of the US government's department of health, after 13 years as director of the vaccine research centre (VRC) of the National Institute of Allergy and Infectious Diseases.

During this period, he provided overall direction of the VRC, including the development of notable vaccine strategies against HIV, ebola, bird flu and SARS.

Prior to joining the NIH, Dr Nabel held several senior research and academic positions, including as director of the centre for gene therapy and co-director of the centre for molecular medicine at the University of Michigan.

It is the second high profile scientific appointment for Sanofi in recent weeks following the appointment of Dr Paul Chew to senior VP, chief medical officer and head of global medical affairs.

19th November 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

New from the PhRMA: Diversity in clinical trials principles summarised
In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
New from the FDA: Diversity in clinical trials guidance summarised
In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....
5 steps to effective clinical trial branding
When recruiting patients for your clinical trial, you want the materials and information around it to be seen as reputable and professional. To make it clear what the clinical trial...

Infographics